Is Incyte Corporation (NASDAQ:INCY) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Incyte Corporation at current levels.
Jakafi cliff is the fear, but Opzelura plus a loaded MPN pipeline reshapes Incyte into something the market hasn't repriced yet.
Where INCY is headed
Incyte in late 2028 looks almost nothing like the Incyte that spent a decade being described as 'the Jakafi company with a pipeline.' Jakafi loses US composition-of-matter protection in December 2028, and that single fact has anchored the stock for years. What it misses is that by the time the cliff arrives, Opzelura (ruxolitinib cream) should be running at a $1.5B+ annual pace across atopic dermatitis, vitiligo, and (pending readouts) prurigo nodularis and hidradenitis suppurativa indications. Povorcitinib, the oral JAK1 inhibitor, has a realistic shot at HS and vitiligo approvals that collectively address markets larger than Jakafi's entire franchise. And the next-generation MPN program (INCA033989, the anti-mutant CALR antibody, plus the mutant-CALR-targeted INCA035784) is doing something nobody else in haematology is doing at scale: going after the actual driver mutation in a subset of MF/ET patients rather than suppressing JAK signalling downstream.
Read the full Compass Direction on INCY
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $113.07).
See the full INCY analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Incyte Corporation (NASDAQ:INCY) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Incyte Corporation at current levels. Jakafi cliff is the fear, but Opzelura plus a loaded MPN pipeline reshapes Incyte into something the market hasn't repriced yet.
What is INCY's Compass Score?
Incyte Corporation scores 76/100 on Alexandria's Compass, placing it in the "Favorable" tier. Scores blend eight factors and update weekly.
What is the price target for INCY?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the INCY page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.